TP53 and neoplasm: The 25 of 120 tumours predicted as LC2/3 by the classifier showed biological profiles consistent with the original UROMOL clusters, including significantly lower FGFR3 (p = 0.045), p53 (p = 0.030) and SHH (p = 0.045) pathway activity (Figure S3).